Here we describe that in vitro treatment of BRAFV600E-mutant melanoma cells with vemurafenib (BRAFi) and trametinib (MEKi), as solo or combined therapies, leads to a downmodulation of surface NK activating ligands (NKG2D and DNAM-1-ligands), which paralleled with a decrease in total MICA protein levels in cell lysates. This evidence concerns the gene MICA and melanoma.